Tag: cardiovascular disease

—

by

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. Lipoprotein(a) lowering is already a mature commercial field: three injectable siRNA/ASO agents are in large cardiovascular-outcome Phase 3 trials at roughly 90%+ Lp(a) reduction, an oral…

Oral muvalaplin and the measurement problem — why half of Lp(a)’s “efficacy gap” may be the ruler, not the drug

—

by

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. Muvalaplin (Eli Lilly, LY3473329) is the first oral, once-daily small molecule that lowers lipoprotein(a) — it blocks assembly of the Lp(a) particle rather than shutting off…

Lp(a) is causal — so how much do you have to lower it? Mendelian randomization, epidemiology and the 2026 guideline turn

—

by

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, and not medical advice. The 30-second version What. The causal case for lipoprotein(a), Lp(a), as a driver of atherosclerotic cardiovascular disease is one of the strongest genetic cases in cardiology — Mendelian randomization…

The Lp(a) landscape — a genetically fixed axis of residual cardiovascular risk, and the first drugs that lower it 90%+ (while the outcome question stays open)

—

by

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. Lipoprotein(a), or Lp(a), is a largely genetically fixed particle that Mendelian randomization (MR) has established as a causal axis of residual cardiovascular risk — the part…

In-vivo gene editing — big pharma bet on the delivery platform, not the editor, and the real bottleneck (hard outcomes) is untouched

—

by

in Biotech

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. In 2025–26 big pharma bought its way into in-vivo gene editing and in-vivo CAR-T (Eli Lilly–Verve up to $1.3B; AbbVie–Capstan up to $2.1B). But the bet…

In-vivo gene editing of the lipid axis — PCSK9, ANGPTL3 and Lp(a), and what a “one-shot, lifelong” lowering does and does not yet prove

—

by

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. The 30-second version What. In-vivo gene editing is now reproducing, in a permanent, single-dose form, the “lipid biomarker lowering” that siRNA/ASO drugs already established. Two programs have reached peer review:…

The in-vivo gene-editing landscape — one-shot, lifelong lipid lowering has arrived at the headline, but delivery, safety and irreversibility are the real bottlenecks

—

by

in Biotech

Evidence-first notes on bioscience and deep tech, at the edge of the lab and the market. Information only — not investment advice, not medical advice. All reduction and editing-efficiency figures are attributed to the sponsoring trial or company; many are company press releases or conference presentations rather than peer-reviewed data (noted inline). Safety events are…

Asia is not a full importer of the CKM/SMD naming war — it selectively adopts MASLD and keeps its own diagnostic thresholds

—

by

Evidence-first notes on bioscience and medical affairs, at the edge of the clinic and the market. Information only — not investment advice, not medical advice. The 30-second version What. Korea and Asia have not officially imported the upper-level CKM/SMD taxonomy into society guidelines. The only nomenclature they have formally adopted is the MASLD renaming (Korean…

The European/global axis annexes the liver — how SMD and MASLD attack the missing organ in the US CKM standard, and why the glue is the drug, not the taxonomy

—

by

Evidence-first notes on bioscience and medical affairs, at the edge of the clinic and the market. Information only — not investment advice, not medical advice. The 30-second version What. Part 1 identified the largest gap in the US CKM standard as the absence of the liver. The European/global axis attacks exactly that gap: the EAS…

Finerenone and the CKM “third pillar” — complementarity is a division of outcomes, and the anti-fibrotic expansion is preclinical-thick but human-empty

Jul 12, 2026

—

by